| Drug Name: | Tacrine (321-64-2) |
|---|---|
| PubChem ID: | 1935 |
| SMILES: | C1CCC2=NC3=CC=CC=C3C(=C2C1)N |
| InchiKey: | YLJREFDVOIBQDA-UHFFFAOYSA-N |
| Therapeutic Category: | Autonomic Agents, Central Nervous System Agents, Cholinergic Agents, Cholinesterase Inhibitors, Enzyme Inhibitors, Neurotransmitter Agents, Nootropic Agents, Parasympathomimetics, Peripheral Nervous System Agents |
| Molecular Weight (dalton) | : | 198.269 |
| LogP | : | 2.6958 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 2 |
| Hydrogen Bond Donor Count | : | 1 |
| Total Polar Surface Area | : | 38.91 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Ibuprofen (15687-27-1) | Delirium | Additive | Unknown | Delirium caused by tacrine and ibuprofen interaction |
| Haloperidol (52-86-8) | Parkinsonism | Additive | Unknown | Severe parkinsonian symptom development on combination treatment with tacrine and haloperidol |
| Levodopa (59-92-7) | Gait Abnormal | Synergistic | Not clear | Exacerbation of parkinsonism by tacrine |
| Levodopa (59-92-7) | Stiffness | Synergistic | Not clear | Exacerbation of parkinsonism by tacrine |
| Levodopa (59-92-7) | Tremor | Synergistic | Not clear | Exacerbation of parkinsonism by tacrine |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Alzheimers Disease | Apolipoprotein E (P02649) | Alzheimer?s disease [ ADR Type 2 ] | Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease |
| Anorexia | Cholinesterase precursor (P06276) | The asthenia and anorexia adverse effect of tacrine are dose related and largely depend on the degree of cholinesterase inhibition@after administration of cholinesterase inhibitors [ ADR Type 1 ] | Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease |
| Asthenia | Cholinesterase precursor (P06276) | The asthenia and anorexia adverse effect of tacrine are dose related and largely depend on the degree of cholinesterase inhibition@after administration of cholinesterase inhibitors [ ADR Type 1 ] | Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease |
| Diarrhoea | Cholinesterase precursor (P06276) | The diarrhoea adverse effect of tacrine are dose related and largely depend on the degree of cholinesterase inhibition@after administration of cholinesterase inhibitors [ ADR Type 1 ] | Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease |
| Dizziness | Cholinesterase precursor (P06276) | The dizziness adverse effect of tacrine are dose related and largely depend on the degree of cholinesterase inhibition@after administration of cholinesterase inhibitors. [ ADR Type 1 ] | Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease |
| Hepatotoxicity | Cytochrome P450 1A2 (P05177) | CBT will not be clinically useful in determining the subset of patients most susceptible to tacrine hepatotoxicity However@ the correlation between CBT results and tacrine blood levels is the first evidence supporting a critical role for CYP1A2 activity in the disposition of the drug in vivo [ ADR Type 2 ] | The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity |
| Nausea | Cholinesterase precursor (P06276) | The nausea and vomiting adverse effect of tacrine are dose related and largely depend on the degree of cholinesterase inhibition@after administration of cholinesterase inhibitors. [ ADR Type 1 ] | Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease |
| Vomiting | Cholinesterase precursor (P06276) | The nausea and vomiting adverse effect of tacrine are dose related and largely depend on the degree of cholinesterase inhibition@after administration of cholinesterase inhibitors. [ ADR Type 1 ] | Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category